SRNE
Sorrento Therapeutics Inc (SRNE)
$2.167.46%▲
Key Stats
$2.06
Day's Range
$2.19
$1.15
52-Week Range
$9.99
| Returns | |
| 1 month return | 29.52% |
| 3 month return | 1.42% |
| 1 year return | 73.84% |
| 5 year return | 10.26% |
Company Information
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ('G-MAB™library'), clinical stage immuno-cellular therapies ('CAR-T', 'DAR-T'), antibody-drug conjugates ('ADCs'), and clinical stage oncolytic virus ('Seprehvir®'). Sorrento is also developing potential coronavirus antiviral therapies and vaccines, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™and COVI-CELL™. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by its effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ('RTX'), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.
| Organization | Sorrento Therapeutics Inc |
| CEO | Henry Ji |
| Industry | Health Technology |
Analyst Recommendation
based on 8 analysts ratings
Buy
87%
Buy
12%
Hold
0%
Sell
Based on 8 Wall street analysts offering stock ratings for Sorrento Therapeutics Inc(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 923.26%Current
$2.15
Target
$22.0
Recommendation Trend
Based on 8 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 7 | 7 | 7 |
| Hold | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 543.2M |
| Book Value | 0.26 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0 |
| Earnings Share | -1.45 |
| PEG Ratio | -0.07 |
| Wall Street Target Price | 21.0 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 1.18 |
| Price/Sales (ttm) | 10.27 |
| Price/Book (mrq) | 7.47 |
| Enterprise Value | 698.6M |
| Enterprise Value/Revenue | 13.21 |
| Enterprise Value/Ebitda | 0.0 |
Technicals
| Beta | 2.31 |
| 50 Day MA | 2.27 |
| 200 Day MA | 5.48 |
Institutional Holdings
State Street Corporation
8.73%
BlackRock Inc
5.6%
Vanguard Group Inc
4.09%
Geode Capital Management, LLC
1.28%
JPMorgan Chase & Co
0.85%
Northern Trust Corp
0.72%
